Carbohydrate Antigen (CA) 19-9
Monitor gastrointestinal, pancreatic, liver, and colorectal malignancies
Additional Test Information:
This assay intended for the in vitro quantitative determination of CA 19-9 tumor-associated antigen in human serum and plasma.1 The assay is indicated for the serial measurement of CA 19-9 to aid in the management of patients diagnosed with cancers of the exocrine pancreas. The test is useful as an aid in the monitoring of disease status in those patients having confirmed pancreatic cancer who have levels of CA 19-9 at some point in their disease process exceeding the median concentration determined for the apparently healthy cohort.
0.3 mL (Note: This volume does not allow for repeat testing.)
Red-top tube or gel-barrier tube
If red-top tube is used, transfer separated serum to a plastic transport tube.
Room temperature 14 days
Refrigerated 14 days
Frozen 14 days
Freeze/thaw cycles Stable x3
Citrate plasma specimen; improper labeling